These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 34132072

  • 1. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
    Xiao L, Shi XY, Li ZL, Li M, Zhang MM, Yan SJ, Wei ZL.
    J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
    [Abstract] [Full Text] [Related]

  • 2. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
    Long X, Song K, Hu H, Tian Q, Wang W, Dong Q, Yin X, Di W.
    J Exp Clin Cancer Res; 2019 Aug 07; 38(1):345. PubMed ID: 31391118
    [Abstract] [Full Text] [Related]

  • 3. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway.
    Sun Y, Jiang T, Jia Y, Zou J, Wang X, Gu W.
    Cell Cycle; 2019 Oct 07; 18(19):2509-2523. PubMed ID: 31397203
    [Abstract] [Full Text] [Related]

  • 4. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S, Felipe-Abrio B, Verdugo-Sivianes EM, Perez M, Jiménez-García MP, Suarez-Martinez E, Estevez-Garcia P, Carnero A.
    Mol Cancer; 2020 Jan 11; 19(1):7. PubMed ID: 31926547
    [Abstract] [Full Text] [Related]

  • 5. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C, Wang M, Shi C, Shi F, Pei C.
    Biosci Trends; 2018 Jul 17; 12(3):309-316. PubMed ID: 29952351
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Downregulation of SSR2 Enhances Hepatocellular Carcinoma Cisplatin Sensitivity via the Hippo Pathway.
    Ye R, Yin L, Ge Y, Zhu X, Xiao Y, Fang C, Liu Q, Zhang H, Li H, Xie B.
    Front Biosci (Landmark Ed); 2024 Aug 21; 29(8):299. PubMed ID: 39206890
    [Abstract] [Full Text] [Related]

  • 9. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
    Chen Y, Cao XY, Li YN, Qiu YY, Li YN, Li W, Wang H.
    Am J Physiol Cell Physiol; 2018 Aug 01; 315(2):C225-C235. PubMed ID: 29719173
    [Abstract] [Full Text] [Related]

  • 10. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P, Hu Y, Qu P, Zhao Y, Liu J, Zhao J, Kong B.
    Bioengineered; 2022 Jan 01; 13(1):1931-1941. PubMed ID: 35001804
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M, Wang J, Guo Y, Yue H, Zhang L.
    J Ovarian Res; 2023 Dec 19; 16(1):240. PubMed ID: 38115063
    [Abstract] [Full Text] [Related]

  • 13. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
    Li X, Zhang Y, Wang X, Lin F, Cheng X, Wang Z, Wang X.
    Cell Biol Toxicol; 2022 Dec 19; 38(6):1027-1045. PubMed ID: 34510316
    [Abstract] [Full Text] [Related]

  • 14. Long non-coding RNA LOC107985656 represses the proliferation of hepatocellular carcinoma cells through activation of the tumor-suppressive Hippo pathway.
    Zeng Y, Xu Q, Xu N.
    Bioengineered; 2021 Dec 19; 12(1):7964-7974. PubMed ID: 34565286
    [Abstract] [Full Text] [Related]

  • 15. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, Han P, Li Y, Liu M, Zhang Z, Li P.
    Cell Death Dis; 2018 Oct 30; 9(11):1103. PubMed ID: 30375398
    [Abstract] [Full Text] [Related]

  • 16. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y, Huang S, Guo Y, Li L.
    Biomed Pharmacother; 2018 Oct 30; 106():1357-1363. PubMed ID: 30119207
    [Abstract] [Full Text] [Related]

  • 17. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J, Liu L.
    J Ovarian Res; 2021 Nov 19; 14(1):165. PubMed ID: 34798882
    [Abstract] [Full Text] [Related]

  • 18. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
    Lin C, Zheng M, Yang Y, Chen Y, Zhang X, Zhu L, Zhang H.
    Bioengineered; 2022 Apr 19; 13(4):9829-9838. PubMed ID: 35412951
    [Abstract] [Full Text] [Related]

  • 19. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L, Sun YH, An R, Cheng RJ, Li N, Zheng JH.
    Kaohsiung J Med Sci; 2023 Aug 19; 39(8):779-788. PubMed ID: 37218642
    [Abstract] [Full Text] [Related]

  • 20. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
    Lu YM, Wang Y, Liu SQ, Zhou MY, Guo YR.
    Oncol Rep; 2018 Nov 19; 40(5):2964-2976. PubMed ID: 30132558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.